Company intelligence / Profile preview

iCell ImmunityX

Ownership: Private
Development stage: Other

Overview

Pioneer in developing proprietary chimeric antigen receptor (CAR) immunotherapies for cancer and autoimmune diseases. First to introduce a successful CAR therapy for lupus with long-term remission. Largest public database of clinical use of CAR therapies for autoimmunity. Also developed first-in-world anti-CD33/CLL1 compound CAR for AML showing strong efficacy.

Therapeutic areas: HematologyImmunologyOncology
Modalities: CAR-T cell therapyCell therapyUniversal CARs (Super NK-cell)Non-gene editing CAR technologyCompound CARs (cCARs)
Industry: Biotech

Beyond the preview

Go deeper on iCell ImmunityX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iCell ImmunityX.

Explore the full profile